[go: up one dir, main page]

TN2011000454A1 - Derives de benzofurannyle utilises comme inhibiteurs de glucokinase - Google Patents

Derives de benzofurannyle utilises comme inhibiteurs de glucokinase

Info

Publication number
TN2011000454A1
TN2011000454A1 TN2011000454A TN2011000454A TN2011000454A1 TN 2011000454 A1 TN2011000454 A1 TN 2011000454A1 TN 2011000454 A TN2011000454 A TN 2011000454A TN 2011000454 A TN2011000454 A TN 2011000454A TN 2011000454 A1 TN2011000454 A1 TN 2011000454A1
Authority
TN
Tunisia
Prior art keywords
glucokinase
benzofurannyl
derivatives
des
glucokinase inhibitors
Prior art date
Application number
TN2011000454A
Other languages
English (en)
Inventor
Anthony Lai Ling
Jeffrey Allen Pfefferkorn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42124287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000454(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of TN2011000454A1 publication Critical patent/TN2011000454A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention propose des composés de formule (I) qui jouent le role d'activateurs de glucokinase; des compositions pharmaceutiques les contenant et des procédés pour le traitement de maladies, de troubles, ou d'affections à médiation par la glucokinase.
TN2011000454A 2009-03-11 2011-09-08 Derives de benzofurannyle utilises comme inhibiteurs de glucokinase TN2011000454A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15909909P 2009-03-11 2009-03-11
PCT/IB2010/050943 WO2010103437A1 (fr) 2009-03-11 2010-03-04 Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase

Publications (1)

Publication Number Publication Date
TN2011000454A1 true TN2011000454A1 (fr) 2013-03-27

Family

ID=42124287

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000454A TN2011000454A1 (fr) 2009-03-11 2011-09-08 Derives de benzofurannyle utilises comme inhibiteurs de glucokinase

Country Status (37)

Country Link
US (2) US8455496B2 (fr)
EP (2) EP2604604A1 (fr)
JP (1) JP5086480B2 (fr)
KR (1) KR101295937B1 (fr)
CN (1) CN102388038B (fr)
AP (1) AP3179A (fr)
AR (1) AR075729A1 (fr)
AU (1) AU2010222589B2 (fr)
BR (1) BRPI1013246B1 (fr)
CA (1) CA2754681C (fr)
CL (1) CL2011002185A1 (fr)
CO (1) CO6430427A2 (fr)
CR (1) CR20110467A (fr)
CU (1) CU24036B1 (fr)
DK (1) DK2406253T3 (fr)
DO (1) DOP2011000279A (fr)
EA (1) EA018894B1 (fr)
EC (1) ECSP11011306A (fr)
ES (1) ES2427279T3 (fr)
GE (1) GEP20156239B (fr)
HR (1) HRP20130661T1 (fr)
IL (1) IL214942A (fr)
MA (1) MA33119B1 (fr)
MY (1) MY151246A (fr)
NI (1) NI201100166A (fr)
NZ (1) NZ595024A (fr)
PE (1) PE20120668A1 (fr)
PL (1) PL2406253T3 (fr)
PT (1) PT2406253E (fr)
RS (1) RS52903B (fr)
SI (1) SI2406253T1 (fr)
TN (1) TN2011000454A1 (fr)
TW (1) TWI383981B (fr)
UA (1) UA99882C2 (fr)
UY (1) UY32480A (fr)
WO (1) WO2010103437A1 (fr)
ZA (1) ZA201106632B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2792234C (fr) 2010-03-19 2014-05-27 Pfizer Inc. Derives de 2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane et leur utilisation en tant qu'antagonistes ou agonistes inverses du recepteur de ghreline
AU2011322117B2 (en) 2010-10-29 2015-01-22 Pfizer Inc. N1/N2-lactam acetyl-CoA carboxylase inhibitors
GEP20166474B (en) 2011-04-22 2016-05-10 Pfizer Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
CA2841757A1 (fr) 2011-07-15 2013-01-24 Etzer Darout Modulateurs de gpr 119
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
SG11201405477XA (en) 2012-04-06 2014-11-27 Pfizer Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2852597B1 (fr) 2012-05-04 2016-06-08 Pfizer Inc Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2931731A1 (fr) 2012-12-11 2015-10-21 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (fr) 2013-02-13 2017-08-09 Pfizer Inc Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
ES2665153T3 (es) 2013-10-09 2018-04-24 Pfizer Inc. Antagonistas del receptor EP3 de prostaglandina
PE20161368A1 (es) 2014-03-17 2016-12-25 Pfizer Inhibidores de diacilglicerol aciltranferasa 2
ME03599B (fr) 2014-04-04 2020-07-20 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
CR20160455A (es) 2014-04-10 2016-12-16 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA
CN104387348A (zh) * 2014-10-27 2015-03-04 湖南华腾制药有限公司 一种苯并呋喃衍生物的制备方法
WO2016092413A1 (fr) 2014-12-10 2016-06-16 Pfizer Inc. Composés indoliques et indazoliques qui activent l'ampk
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
SI3265126T1 (sl) 2015-03-03 2021-11-30 Saniona A/S Formulacija kombinacije tezofenzina in metoprolola
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
WO2016193844A1 (fr) 2015-05-29 2016-12-08 Pfizer Inc. Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1
CR20170572A (es) 2015-06-17 2018-03-20 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
WO2016203335A1 (fr) 2015-06-18 2016-12-22 Pfizer Inc. Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet
WO2017025849A1 (fr) 2015-08-13 2017-02-16 Pfizer Inc. Composés aryle ou hétéroaryle condensés bicycliques
AU2016311376B2 (en) 2015-08-27 2018-10-04 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
WO2017037567A1 (fr) 2015-09-03 2017-03-09 Pfizer Inc. Régulateurs de la frataxine
WO2017051294A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides utiles comme inhibiteurs de bace
WO2017051276A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
WO2017051303A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. Dérivés de tétrahydropyrano[3,4-d] [1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
ES2871251T3 (es) 2015-12-29 2021-10-28 Pfizer 3-Azabiciclo[3.1.0]Hexanos sustituidos como inhibidores de la cetohexocinasa
CA3030381A1 (fr) 2016-07-14 2018-01-18 Pfizer Inc. Pyrimidine carboxamides utilisees comme inhibiteurs de l'enzyme vanin-1
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
WO2019133445A1 (fr) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
PT3804716T (pt) * 2018-05-31 2025-03-05 Hua Medicine Shanghai Ltd Combinação farmacêutica, composição e preparação de combinação, incluindo ativador de glucoquinase e inibidor de sglt-2 e seus métodos de preparação e utilizazão
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
US20210338776A1 (en) * 2018-09-06 2021-11-04 Yale University Treatments against mosquito-borne viruses based on mosquito salivary gland proteins
WO2020102575A1 (fr) 2018-11-16 2020-05-22 Inception Ibd, Inc. Aminothiazoles hétérocycliques et leurs utilisations
ES3039586T3 (en) 2019-05-20 2025-10-22 Pfizer Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CA3144848C (fr) 2019-06-28 2023-11-21 Pfizer Inc. Derives de 5-(thiophen-2-yl) -1h-tetrazole utilises en tant qu'inhibiteurs de bckdk utiles pour le traitement de diverses maladies
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
MA58498B1 (fr) 2020-02-07 2024-08-30 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
RS65929B9 (sr) 2020-06-09 2025-02-28 Pfizer Spiro jedinjenja kao antagonisti receptora melanokortina 4 i njihova upotreba
WO2023026180A1 (fr) 2021-08-26 2023-03-02 Pfizer Inc. Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide
EP4441037A1 (fr) 2021-12-01 2024-10-09 Pfizer Inc. Dérivés d'acide 3-phényl-1-benzothiophène-2-carboxylique utilisés en tant qu'inhibiteurs de kinase alpha-céto-acide à chaîne ramifiée pour le traitement du diabète, de maladies rénales, de la shna et de l'insuffisance cardiaque
JP2024544021A (ja) 2021-12-06 2024-11-26 ファイザー・インク メラノコルチン４受容体アンタゴニストおよびそれらの使用
WO2023169456A1 (fr) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Agonistes hétérocycliques de glp-1
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4598908A1 (fr) 2022-10-07 2025-08-13 Pfizer Inc. Inhibiteurs et/ou agents de dégradation de hsd17b13
AU2023364628A1 (en) 2022-10-18 2025-04-03 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024118524A1 (fr) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase
WO2024125602A1 (fr) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Sels et formes solides d'un composé ayant une activité agoniste de glp-1
KR20250117453A (ko) 2022-12-16 2025-08-04 화이자 인코포레이티드 3-플루오로-4-하이드록시벤즈아미드-함유 억제제 및/또는 분해제 및 이의 용도
CN121311466A (zh) 2023-04-14 2026-01-09 辉瑞大药厂 葡萄糖依赖性促胰岛素多肽受体拮抗剂及其用途
WO2025099566A1 (fr) 2023-11-08 2025-05-15 Pfizer Inc. Forme cristalline d'acide 6-fluoro-3-(2,4,5-trifluoro-3-méthoxyphényl)-1-benzothiophène-2-carboxylique
TW202539633A (zh) 2024-02-01 2025-10-16 美商輝瑞股份有限公司 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2025224599A1 (fr) 2024-04-22 2025-10-30 Pfizer Inc. Antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose à base de pyrrolidine et leurs utilisations
WO2026013531A1 (fr) 2024-07-10 2026-01-15 Pfizer Inc. Composés spiro[2,5]octane

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795984A (en) * 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
EP0606489A4 (fr) 1992-07-03 1995-01-25 Kumiai Chemical Industry Co Derive heterocyclique condense et desherbant.
AU702346B2 (en) * 1994-07-22 1999-02-18 Altana Pharma Ag Dihydrobenzofuranes
DE4434637A1 (de) 1994-09-28 1996-04-04 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
CN1166834A (zh) * 1994-10-13 1997-12-03 美国辉瑞有限公司 苯并吡喃和苯并稠合化合物，其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途
NZ285156A (en) * 1994-10-13 1999-01-28 Pfizer Benzopyran and benzo-fused compounds, preparation and use as leukotriene b4 antagonists (ltb4)
DE19603576A1 (de) 1996-02-01 1997-08-07 Bayer Ag Acylierte 4-Amino und 4-Hydrazinopyrimidine
US5972936A (en) * 1996-05-20 1999-10-26 Darwin Discover Limited Benzofuran carboxamides and their therapeutic use
DK0923568T5 (da) * 1996-08-19 2003-11-03 Altana Pharma Ag Hidtil ukendte benzofuran-4-carboxamider
AU2529799A (en) * 1998-02-09 1999-08-23 Darwin Discovery Limited Benzofuran-4-carboxamides and their therapeutic use
ATE455106T1 (de) * 1999-01-22 2010-01-15 Elan Pharm Inc Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
WO2002020463A2 (fr) 2000-09-05 2002-03-14 Tularik Inc. Modulateurs fxr
CA2436854A1 (fr) 2000-11-20 2002-05-23 Bristol-Myers Squibb Company Derives de pyridones utilises en tant qu'inhibiteurs ap2
DE60117059T2 (de) 2000-12-06 2006-10-26 F. Hoffmann-La Roche Ag Kondensierte heteroaromatische glucokinaseaktivatoren
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
WO2002068388A2 (fr) 2001-02-28 2002-09-06 Merck & Co., Inc. Derives de piperidine acylee tels que les agonistes du recepteur 4 de la melanocortine
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
JP4623962B2 (ja) 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
ATE448784T1 (de) 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
CN100357283C (zh) * 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
WO2003092670A1 (fr) 2002-05-03 2003-11-13 Warner-Lambert Company Llc Antagonistes de bombesine
JP4287816B2 (ja) 2002-06-13 2009-07-01 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー ピラゾールカルボキサミド殺虫剤
JP4302967B2 (ja) * 2002-11-18 2009-07-29 パイオニア株式会社 楽曲検索方法、楽曲検索装置及び楽曲検索プログラム
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1433778A1 (fr) 2002-12-23 2004-06-30 Jerini AG Utilisation de nitriles en tant qu'inhibiteurs de rotamase
WO2004072066A1 (fr) 2003-02-11 2004-08-26 Prosidion Limited Composes d'amide a substitution tri(cyclo), activateurs de la glucokinase
UA82867C2 (en) * 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
CN100378094C (zh) * 2003-02-13 2008-04-02 万有制药株式会社 2-吡啶甲酰胺衍生物
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
KR20050105488A (ko) * 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 헤테로아릴카바모일벤젠 유도체
US20060205751A1 (en) * 2003-07-15 2006-09-14 Smithkline Beecham Corporation Novel compounds
CA2533747C (fr) * 2003-08-01 2012-11-13 Chugai Seiyaku Kabushiki Kaisha Composes heterocycliques utiles comme inhibiteurs de la malonyl-coa decarboxylase
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
EP1532980A1 (fr) 2003-11-24 2005-05-25 Novo Nordisk A/S Carboxamides d'indole n-heteroarylé et leurs analogues, utiles comme des activateurs de glucokinase pour le traitement de diabetes
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
EP1753766A1 (fr) 2004-05-25 2007-02-21 Pfizer Products Inc. Derives de tetraazabenzo(e)azulene et analogues de ceux-ci
WO2006015159A2 (fr) 2004-07-29 2006-02-09 Merck & Co., Inc. Inhibiteurs de canal a potassium
EP1786783A1 (fr) 2004-09-01 2007-05-23 Rigel Pharmaceuticals, Inc. Synthese de composes de 2,4-pyrimidinediamine
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
SE0403006D0 (sv) * 2004-12-09 2004-12-09 Biovitrum Ab New compounds
PL1831191T3 (pl) * 2004-12-21 2008-10-31 Hoffmann La Roche Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
JP4167218B2 (ja) 2004-12-22 2008-10-15 株式会社メタル建材 薄板用タッピンねじ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
US20090275570A1 (en) 2005-04-06 2009-11-05 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
AU2006285834A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
JP2009013065A (ja) * 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
CN101360720A (zh) 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶酮衍生物及其用途
JP5302012B2 (ja) * 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
WO2007117995A2 (fr) 2006-03-30 2007-10-18 Takeda San Diego, Inc. Inhibiteurs de kinase
US7842713B2 (en) * 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
SI2463283T1 (sl) * 2006-04-20 2014-09-30 Pfizer Products Inc. Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza
WO2008079787A2 (fr) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Activateurs de glucokinase
JP2010138073A (ja) 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
US8299115B2 (en) 2007-06-08 2012-10-30 Debnath Bhuniya Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
JP2012515760A (ja) * 2009-01-20 2012-07-12 ファイザー・インク 置換ピラジノンアミド

Also Published As

Publication number Publication date
KR20110123288A (ko) 2011-11-14
IL214942A (en) 2015-10-29
BRPI1013246B1 (pt) 2019-10-01
ECSP11011306A (es) 2011-10-31
UY32480A (es) 2010-10-29
UA99882C2 (uk) 2012-10-10
HRP20130661T1 (en) 2013-08-31
CA2754681A1 (fr) 2010-09-16
TWI383981B (zh) 2013-02-01
CL2011002185A1 (es) 2012-02-03
ES2427279T3 (es) 2013-10-29
NZ595024A (en) 2013-01-25
MA33119B1 (fr) 2012-03-01
PE20120668A1 (es) 2012-06-01
EP2604604A1 (fr) 2013-06-19
EA201190158A1 (ru) 2012-04-30
WO2010103437A1 (fr) 2010-09-16
AP2011005882A0 (en) 2011-10-31
CN102388038B (zh) 2014-04-23
ZA201106632B (en) 2012-05-30
CU24036B1 (es) 2014-10-30
BRPI1013246A2 (pt) 2016-04-05
EP2406253B1 (fr) 2013-07-03
EA018894B1 (ru) 2013-11-29
US8455496B2 (en) 2013-06-04
US8735396B2 (en) 2014-05-27
TW201036961A (en) 2010-10-16
EP2406253A1 (fr) 2012-01-18
MY151246A (en) 2014-04-30
CN102388038A (zh) 2012-03-21
CR20110467A (es) 2011-10-07
RS52903B (sr) 2014-02-28
PL2406253T3 (pl) 2013-10-31
AP3179A (en) 2015-03-31
KR101295937B1 (ko) 2013-08-14
DK2406253T3 (da) 2013-08-12
CU20110168A7 (es) 2012-02-15
NI201100166A (es) 2012-01-23
AU2010222589A1 (en) 2011-09-22
SI2406253T1 (sl) 2013-09-30
IL214942A0 (en) 2011-11-30
CA2754681C (fr) 2014-01-07
DOP2011000279A (es) 2011-10-15
PT2406253E (pt) 2013-09-11
GEP20156239B (en) 2015-01-26
CO6430427A2 (es) 2012-04-30
JP5086480B2 (ja) 2012-11-28
HK1164281A1 (en) 2012-09-21
AU2010222589B2 (en) 2012-08-16
US20100234285A1 (en) 2010-09-16
US20130252973A1 (en) 2013-09-26
AR075729A1 (es) 2011-04-20
JP2012520286A (ja) 2012-09-06

Similar Documents

Publication Publication Date Title
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA33492B1 (fr) Inhibiteurs de bace
MY148634A (en) Pyridazinone derivatives
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA31419B1 (fr) Derives de pyridine
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
TN2009000028A1 (fr) Agonistes de ep2
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA32257B1 (fr) Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
MX2009006630A (es) Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
JO2686B1 (en) Vehicles
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
TN2012000146A1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA33428B1 (fr) Agonistes du gpr119
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
MX2008014004A (es) 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
TN2009000033A1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques